Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned new fundraising through debt or equity in the transcript. Net debt as of June 30, 2024, stood at CHF 164 million, with no direct commentary on raising new debt. The company expects to keep CAPEX largely maintenance-focused without significant growth CAPEX, which suggests no immediate large funding needs. There is no indication from management about equity fundraising or debt refinancing plans in the Q&A. Financial strategy seems to focus on improving operating performance and cash flow to manage existing obligations rather than new funding rounds.

Any current/future capex/capital investment/strategic investment?

No significant growth CAPEX is expected in the near future. CAPEX will mainly focus on maintenance and compliance to ensure GMP compliance. Maintenance CAPEX is estimated to be around Rs. 17-18 crores annually. Recent investments include a new French facility worth about €50 million, which has just started generating revenue and is currently underutilized. Potential for revenue increase exists across various group facilities without requiring major new CAPEX. Strategic focus is on improving utilization and operational efficiency rather than large new capital investment.

Future growth expectations in sales/revenue/volumes?

India CRAMS business expected to grow significantly post regulatory clearance, targeting Rs. 325-350 crores revenue for FY 2025, with further growth in subsequent years closer to Rs. 400 crores. Swiss entity anticipated to deliver growth year-over-year on both development and commercial fronts; aiming to exceed CHF 200 million revenue for FY 2025. Overseas entities (Swiss, Dutch, Shanghai, Manchester) have capacity to improve utilization and revenues. French facility, recently started, currently unutilized; expected to ramp up and reduce losses by Q3 FY 2025. Overall group expects about 10% in

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets about 10% top-line growth for the current financial year with potential upside depending on Q2 and Q3 performance. EBITDA margin is expected to improve to approximately 18% for FY25, higher than last year due to reduced goodwill write-offs and operational improvements. Q2 is anticipated to return to the 18% EBITDA margin run rate, supporting annual targets. The India CRAMS business is projected to grow from Rs. 250 crores to Rs. 325-350 crores revenue in FY25, with further upside expected in subsequent years. Europe entities, especially Swiss and Dutch, foresee mode

Current/ Expected Orderbook/ Pending Orders?

The company has a large product portfolio of orders to process in the coming months, especially at the new drug product facility in France and the Swiss facility. There is noticeable traction and increasing orders from existing and new customers at the India site following regulatory clearances. The Swiss entity has a strong orderbook across drug substance, drug product, and specialty segments, supporting confidence in meeting annual targets despite Q3 disappointments. Globally, there is a substantial number of purchase orders in the pipeline, with positive demand from pharma and non-pha

Dishman CarbogenQ1 FY25Pharmaceuticals & Biotechnology

Dishman Carbogen Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹150P/E: 145.4Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

India CRAMS business expected to grow significantly post regulatory clearance, targeting Rs. 325-350 crores revenue for FY 2025, with further growth in subsequent years closer to Rs. 400 crores.
Swiss entity anticipated to deliver growth year-over-year on both development and commercial fronts; aiming to exceed CHF 200 million revenue for FY 2025.
Overseas entities (Swiss, Dutch, Shanghai, Manchester) have capacity to improve utilization and revenues.
French facility, recently started, currently unutilized; expected to ramp up and reduce losses by Q3 FY 2025.
Overall group expects about 10% incremental revenue growth over last year.
Potential positive impact from global pharma shifts (e.g., sourcing away from China) benefiting European and Indian operations.
Maintenance CAPEX expected around Rs. 17-18 million annually; no major growth CAPEX anticipated.

Margin guidance

Category 1

The company targets about 10% top-line growth for the current financial year with potential upside depending on Q2 and Q3 performance.
EBITDA margin is expected to improve to approximately 18% for FY25, higher than last year due to reduced goodwill write-offs and operational improvements.
Q2 is anticipated to return to the 18% EBITDA margin run rate, supporting annual targets.
The India CRAMS business is projected to grow from Rs. 250 crores to Rs. 325-350 crores revenue in FY25, with further upside expected in subsequent years.
Europe entities, especially Swiss and Dutch, foresee modest single-digit growth in revenues, recovering from cost pressures.
Overall, operating profits should be significantly higher than last year, with positive profit after tax likely in the current financial year.
The company does not expect major CAPEX, focusing on maintenance and compliance, which supports improving returns.

See what Dishman Carbogen management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned new fundraising through debt or equity in the transcript.
Net debt as of June 30, 2024, stood at CHF 164 million, with no direct commentary on raising new debt.
The company expects to keep CAPEX largely maintenance-focused without significant growth CAPEX, which suggests no immediate large funding needs.
There is no indication from management about equity fundraising or debt refinancing plans in the Q&A.
Financial strategy seems to focus on improving operating performance and cash flow to manage existing obligations rather than new funding rounds.

Order book

The company has a large product portfolio of orders to process in the coming months, especially at the new drug product facility in France and the Swiss facility.
There is noticeable traction and increasing orders from existing and new customers at the India site following regulatory clearances.
The Swiss entity has a strong orderbook across drug substance, drug product, and specialty segments, supporting confidence in meeting annual targets despite Q3 disappointments.
Globally, there is a substantial number of purchase orders in the pipeline, with positive demand from pharma and non-pharma markets (cosmetics).
Collaborative efforts are ongoing between Swiss and Bavla (India) sites to transfer projects and increase order fulfillment capacity.
Management remains optimistic about orderbook growth and achieving stronger financial performance for the full year.

See what Dishman Carbogen management said on order book — free account, 30 seconds.

Capex plans

No significant growth CAPEX is expected in the near future.
CAPEX will mainly focus on maintenance and compliance to ensure GMP compliance.
Maintenance CAPEX is estimated to be around Rs. 17-18 crores annually.
Recent investments include a new French facility worth about €50 million, which has just started generating revenue and is currently underutilized.
Potential for revenue increase exists across various group facilities without requiring major new CAPEX.
Strategic focus is on improving utilization and operational efficiency rather than large new capital investment.

Track Dishman Carbogen — get its next earnings analysis in your feed

How does Dishman Carbogen rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisDishman Carbogen

Rev 3Mar 1

See where Dishman Carbogen sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Dishman Carbogen rank in Pharmaceuticals & Biotechnology?

Compare Dishman Carbogen against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Dishman Carbogen's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →